Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Stock Information for Compass Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Compass Therapeutics Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Compass Therapeutics Provides Corporate Update
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics Announces Key Leadership Appointments

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.